McInnes IB, Rahman P, Gottlieb AB, et al. - Treatment with guselkumab (an IL-23p19-subunit inhibitor) in biologic-naïve psoriatic arthritis (PsA) patients resulted in durable improvements in multiple disease domains with no unexpected safety findings through 2 years.

• A total of 739 patients with active PsA despite prior nonbiologic therapy were randomized to: guselkumab 100mg every-4-weeks (Q4W); at Week0, Week4, and Q8W; or placebo➔guselkumab Q4W at Week24, in the phase-3 DISCOVER-2 trial.

• Overall 652 (88%) completed treatment through Week100.

• Guselkumab-induced relief of arthritis signs/symptoms and extra-articular manifestations was durable through 2 years.

• Rates of radiographic progression were low among guselkumab-treated patients at earlier timepoints extended through Week100.

• A serious adverse event or serious infection occurred in 8% and 3% of 731 guselkumab-treated patients, respectively, through Week112; one death was documented (road traffic accident).